Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Medigene expands patent portfolio
June 2020
SHARING OPTIONS:

MUNICH & MARTINSRIED, Germany—Medigene AG announced the receipt of two patents in April—one from the Japanese Patent Office (JP6676759) and one from the New Zealand Patent Office (NZ7741954)—covering the company’s CrossTAg-1 technology. This platform enables cross-presentation of antigens on class I and II Major Histocompatibility Complex (MHC) molecules, also known as human leukocyte antigens (HLA) in humans. Medigene Immunotherapies GmbH and Helmholtz Zentrum München are co-applicants for the patents.
 
Prof. Dolores J. Schendel, CEO and chief scientific officer of Medigene, said, “The granted patents are of particular relevance for the further development of our immunotherapies, as the novel technology assures that we can activate both helper T cells and cytotoxic T cells specific for peptides derived from the same cancer antigen. In patients, the interaction of both types of T cells is needed for best immunity to ultimately fight and control the cancer.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.